Ryszard Zebrak
Psychiatry · Fredericksburg, VANPI 1679523799
Payments from drug & device makers
Across 218 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Sunovion Pharmaceuticals Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$847
- Teva Pharmaceuticals USA, Inc.$194
- Otsuka America Pharmaceutical, Inc.$108
- E.r. Squibb & Sons, L.L.C.$98
- plus $183 from 4 others
What the payments were for
- Food & beverage$4,22598%
- Education$882%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 95 | $1,658 |
| Sunovion Pharmaceuticals Inc. | 58 | $1,226 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 38 | $847 |
| Teva Pharmaceuticals USA, Inc. | 9 | $194 |
| Otsuka America Pharmaceutical, Inc. | 5 | $108 |
| E.r. Squibb & Sons, L.L.C. | 4 | $98 |
| Alkermes, Inc. | 4 | $82 |
| Neurocrine Biosciences, Inc. | 3 | $64 |
| Johnson & Johnson | 1 | $21 |
| Lilly USA, LLC | 1 | $15 |
How this compares
$4,314 in reported general payments places this provider in the 85th percentile of 884 psychiatry providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 76 | $114,383 |
| RexultiBrexpiprazole | 41 | $63,408 |
| AustedoDeutetrabenazine | 11 | $60,712 |
| TrintellixVortioxetine Hydrobromide | 33 | $16,353 |
| Aripiprazole | 186 | $13,635 |
| Quetiapine Fumarate | 349 | $3,890 |
| Oxcarbazepine | 97 | $3,455 |
| Mirtazapine | 265 | $2,467 |
| Ramelteon | 13 | $2,456 |
| Zolpidem Tartrate | 291 | $2,398 |
| Lurasidone Hcl | 49 | $2,290 |
| Alprazolam | 328 | $2,263 |
| Bupropion XlBupropion Hcl | 151 | $2,167 |
| Clonazepam | 108 | $1,322 |
| Amitriptyline Hcl | 19 | $1,205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,658 | $114,38376 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $108 | $63,40841 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $194 | $60,71211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Fredericksburg
- John SwingFredericksburg$63K
- Niku SinghFalls Church$2.5M
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
- Jasdeep MiglaniManassas$958K
- Frederick MoellerRichmond$678K
- David SpiegelNorfolk$565K
- Christopher van EyckStafford$392K
- Anita ClaytonCharlottesville$356K
- Anita KablingerRoanoke$333K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.